Abstract
Depression is a major health issue, which is routinely treated with selective serotonin reuptake inhibitors. However, although these agents display a favorable effect on mood, they often fail to improve conditions that accompany depression including cognitive impairment and fatigue. In pre-clinical studies histamine H3 receptor antagonists have demonstrated both pro-cognitive and wake-promoting effects suggesting that the combination of a histamine H3 receptor antagonist and a serotonin reuptake inhibitor may have utility as an antidepressant therapy. To this end we sought to introduce histamine H3 receptor antagonist activity into both known selective serotonin reuptake inhibitors and novel templates. These efforts have afforded several series of compounds with the desired activities. Selected examples demonstrated in vivo efficacy both in pre-clinical models of depression and wakefulness.
Keywords: Histamine, histamine H3 receptor, histamine H3 receptor antagonists, serotonin, serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT), selective serotonin reuptake inhibitors (SSRIs), depression, wakefulness
Current Topics in Medicinal Chemistry
Title: Exploration of Structure-Activity Relationships for Dual Serotonin Transporter Reuptake Inhibitors-Histamine H3 Receptor Antagonists
Volume: 10 Issue: 5
Author(s): Emily M. Stocking, Michael A. Letavic, Pascal Bonaventure and Nicholas I. Carruthers
Affiliation:
Keywords: Histamine, histamine H3 receptor, histamine H3 receptor antagonists, serotonin, serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT), selective serotonin reuptake inhibitors (SSRIs), depression, wakefulness
Abstract: Depression is a major health issue, which is routinely treated with selective serotonin reuptake inhibitors. However, although these agents display a favorable effect on mood, they often fail to improve conditions that accompany depression including cognitive impairment and fatigue. In pre-clinical studies histamine H3 receptor antagonists have demonstrated both pro-cognitive and wake-promoting effects suggesting that the combination of a histamine H3 receptor antagonist and a serotonin reuptake inhibitor may have utility as an antidepressant therapy. To this end we sought to introduce histamine H3 receptor antagonist activity into both known selective serotonin reuptake inhibitors and novel templates. These efforts have afforded several series of compounds with the desired activities. Selected examples demonstrated in vivo efficacy both in pre-clinical models of depression and wakefulness.
Export Options
About this article
Cite this article as:
Stocking Emily M., Letavic Michael A., Bonaventure Pascal and Carruthers Nicholas I., Exploration of Structure-Activity Relationships for Dual Serotonin Transporter Reuptake Inhibitors-Histamine H3 Receptor Antagonists, Current Topics in Medicinal Chemistry 2010; 10 (5) . https://dx.doi.org/10.2174/156802610791111515
DOI https://dx.doi.org/10.2174/156802610791111515 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [ Migraine Guest Editor: Dimos D. Mitsikostas ]
CNS & Neurological Disorders - Drug Targets Current Neuropharmacology Volume 9, Supplement 1, September 2011
Current Neuropharmacology Vascular Injury During Elevated Glucose can be Mitigated by Erythropoietin and Wnt Signaling
Current Neurovascular Research Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Current Drug Targets Investigation of Low Dose Cabazitaxel Potential as Microtubule Stabilizer in Experimental Model of Alzheimer's Disease: Restoring Neuronal Cytoskeleton
Current Alzheimer Research Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes
Current Stem Cell Research & Therapy Winning a Won Game: Caffeine Panacea for Obesity Syndemic
Current Neuropharmacology Pseudomonas aeruginosa MTCC 7925: Producer of a Novel SCL-LCLPHA Co-Polymer
Current Biotechnology Antioxidant and Enzyme Inhibitory Properties of Mangifera indica leaf Extract
The Natural Products Journal Synthetic Opioid Use and Common Injection-associated Viruses: Expanding the Translational Research Agenda
Current HIV Research In Silico and In Vitro: Identifying New Drugs
Current Drug Targets Phytochemicals Formulated As Nanoparticles: Inventions, Recent Patents and Future Prospects
Recent Patents on Drug Delivery & Formulation Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Interfacial Phenomena: Effects of Confined Space and Structure of Adsorbents on the Behavior of Polar and Nonpolar Adsorbates at Low Temperatures
Current Physical Chemistry Role of Osmolytes in Regulating Immune System
Current Pharmaceutical Design The Impact of Gynecological Cancer on Reproductive Issues and Pregnancy:Psychological Implications
Current Women`s Health Reviews Inflammation, High Density Lipoprotein and Endothelium
Current Medicinal Chemistry Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment
Current Neuropharmacology Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis
Current Medicinal Chemistry Oxytocin and Eating Disorders: A Narrative Review on Emerging Findings and Perspectives
Current Neuropharmacology